Single-Use Systems: Enabling the Future of Biologics Manufacturing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Single-Use Systems: Enabling the Future of Biologics Manufacturing

Pharmaceutical Technology Europe
Volume 26, Issue 8, pp. 40
PharmTech Europe 25th Anniversary
DSGpro/Getty Images;
Art direction: Dan Ward

Single-Use Technology—From Evolution to Revolution

Single-use technologies continue to evolve rapidly as more biopharmaceutical companies embrace the concept and start implementing single-use systems in their bioprocesses.

It would be hard to overstate the impact that single-use systems are having on the biologics manufacturing industry. What started off as a tool for small-volume solution storage and transport has now become the central, enabling technology around which manufacturing processes and facilities are being designed. Several developments in the industry are driving this change. Within development laboratories, scientists have pushed product titers in cell cultures to levels that are commonly 20-fold higher than those realised 15 years ago.

Pharmaceutical Technology Europe
25th Anniversary Issue

Trends in Single-Use Biomanufacturing

Single-Use: Game-Changing Technology for the Biopharmaceutical Industry

Biosimilars (i.e., follow-on versions of innovator biologic products that are at or near patent expiry) offer the opportunity for companies to commercialise products in a condensed timeline for an existing patient population. Given the enormous revenue of some innovator products, the ability to win even a small share of the existing market or open up new markets can be a rich reward to the biosimilar producer. Further, the desire of many governments to have “in-country, for-country” manufacturing of drugs for their population has created the need for smaller, light-asset production facilities designed to meet the local demand.

These developments have driven focus to the 2000-L single-use bioreactor as the centre piece of future manufacturing strategies. The productivity of the current 2000-L single-use bioreactor meets or exceeds that of the 20,000-L stainless-steel bioreactor of legacy processes, with all of the benefits of a single-use system. These include reduced utility requirements for steam-in-place and clean-in-place operations, faster turnover times between batches or products and reduced risk of cross-contamination.

Operation at the 2000-L bioreactor scale also enables the implementation of single-use systems throughout the manufacturing process, most notably in media and buffer preparation and intermediate product mixing and hold steps, and in many cases, fully disposable chromatography, tangential flow filtration, and clarification and virus filtration operations.

Even at the final filling stage, adoption of single-use technology is growing rapidly. The facility to operate these processes can be built, commissioned and qualified in 12 to 18 months at capital costs that are a fraction of a traditional facility. This allows companies to move aggressively into the biosimilars market at lower financial risk and, more importantly, allows for production of much needed medicines closer to the patient regardless of their location. This is the promise and the power of single-use systems.

Michael Felo
Michael Felo

About the Author
Michael Felo is group product manager, Single Use, at EMD Millipore.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology Europe,
Click here